Ran Furman
About Ran Furman
Ran Furman is a Senior Scientist at Bristol-Myers Squibb, with extensive experience in microbiology and drug development.
Current Title at Bristol-Myers Squibb
Ran Furman holds the position of Senior Scientist at Bristol-Myers Squibb. Based in New Brunswick, NJ, he is deeply involved in leading the structure-function analysis of antibodies, fusion proteins, bispecifics, and other biologic drugs. His responsibilities also include managing multidisciplinary teams in scientific investigations of clinical drugs.
Previous Role at Siemens Healthineers
In 2017, Ran Furman worked for Siemens Healthineers as a Senior Biochemist. During his six-month tenure in Delaware, United States, he contributed to various biochemical projects, applying his expertise in the domain of biochemistry and health sciences.
Academic Positions at University of Pennsylvania
From 2013 to 2018, Ran Furman served as a postdoctoral fellow and lab manager at the University of Pennsylvania. Based in the Greater Philadelphia Area, his role encompassed facilitating laboratory operations and conducting advanced research in his field of expertise.
Research Experience at The Ohio State University
Between 2008 and 2013, Ran Furman worked as a Research Assistant at The Ohio State University in Columbus, Ohio Area. His work primarily involved conducting detailed research projects while pursuing his Doctor of Philosophy (Ph.D.) in Microbiology. His doctoral studies equipped him with comprehensive knowledge in the field of microbiology and research methodologies.
Educational Background in Microbiology
Ran Furman has an extensive academic background in Microbiology. He earned his Doctor of Philosophy (Ph.D.) from The Ohio State University, studying in the field from 2008 to 2013. Before that, he completed his Master’s Degree in Microbiology from Tel Aviv University, where he studied from 2001 to 2006. He also holds a Bachelor’s Degree in Life Sciences, which he obtained from Tel Aviv University from 2001 to 2004.
Scientific Leadership and Contributions
Ran Furman serves as the Scientific Leader for multiple drug assets, including those targeting viral, oncology, cardiovascular, and immunomodulator conditions. He has authored multiple sections in Investigational New Drug (IND), post-IND amendments, Biologics License Application (BLA), and FDA filing steps. Further, he developed the Biophysical and Chemical Protein Characterization department curriculum to educate about the multiple steps of drug development.